The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma

Nature Cell Biology

Volumn 16, Issue 3, 2014, Pages 255-267

  Von Figura, Guido ^a,b   Fukuda, Akihisa ^a,c   Roy, Nilotpal ^a   Liku, Muluye E ^a   Morris Iv, John P ^a   Kim, Grace E ^a   Russ, Holger A ^a   Firpo, Matthew A ^d,e   Mulvihill, Sean J ^d,e   Dawson, David W ^f   Ferrer, Jorge ^g   Mueller, William F ^h   Busch, Anke ^h   Hertel, Klemens J ^h   Hebrok, Matthias ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; K RAS PROTEIN;

ACINAR CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; FEMALE; GENE DELETION; HEMIZYGOSITY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CELL; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; ANIMALS; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA HELICASES; FEMALE; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; NUCLEAR PROTEINS; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSCRIPTION FACTORS;

EID: 84895432066     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2916     Document Type: Article

References (61)

1. Matthaei, H., Schulick, R. D., Hruban, R. H. & Maitra, A. Cystic precursors to invasive pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 141-150 (2011).
2. Matthaei, H. et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann. Surg. 255, 326-333 (2012).
3. Poultsides, G. A. et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann. Surg. 251, 470-476 (2010).
4. Mino-Kenudson, M. et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60, 1712- 1720 (2011).
5. Shi, C. & Hruban, R. H. Intraductal papillary mucinous neoplasm. Hum. Pathol. 43, 1-16 (2012).
6. Ray, K. C. et al. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One 6, e16786 (2011).
7. Visvader, J. E. Cells of origin in cancer. Nature 469, 314-322 (2011).
8. Habbe, N. et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad. Sci. USA 105, 18913-18918 (2008).
9. Kopp, J. L. et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22, 737-750 (2012).
10. Morris, J. P. t., Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683-695 (2010).
11. von Figura, G., Morris, J. P. t., Wright, C. V. & Hebrok, M. Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation. Gut http://dx.doi.org/10.1136/gutjnl-2012- 304287 (2013).
12. McKenna, E. S. & Roberts, C. W. Epigenetics and cancer without genomic instability. Cell Cycle 8, 23-26 (2009).
13. Wilson, B. G. & Roberts, C. W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481-492 (2011).
14. Medina, P. P. & Sanchez-Cespedes, M. Involvement of the chromatin-remodelling factor BRG1/SMARCA4 in human cancer. Epigenetics 3, 64-68 (2008).
15. Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203-206 (1998).
16. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
17. Li, M. et al. Inactivating mutations of the chromatin remodelling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828-829 (2011).
18. Gui, Y. et al. Frequent mutations of chromatin remodelling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875-878 (2011).
19. Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010).
20. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
21. Roberts, C. W., Leroux, M. M., Fleming, M. D. & Orkin, S. H. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumour suppressor gene Snf5. Cancer Cell 2, 415-425 (2002).
22. Roberts, C. W., Galusha, S. A., McMenamin, M. E., Fletcher, C. D. & Orkin, S. H. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumours in mice. Proc Natl Acad. Sci. USA 97, 13796-13800 (2000).
23. Glaros, S., Cirrincione, G. M., Palanca, A., Metzger, D. & Reisman, D. Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res. 68, 3689-3696 (2008).
24. Jones, S. et al. Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
25. E Shain, A. H. et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumour suppressive complex in pancreatic cancer. Proc Natl Acad. Sci. USA 109, 252-259 (2012).
26. Dal Molin, M. et al. Loss of expression of the SWI/SNF chromatin remodelling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum. Pathol. 43, 585-591 (2012).
27. Sumi-Ichinose, C., Ichinose, H., Metzger, D. & Chambon, P. SNF2β-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol. Cell Biol. 17, 5976-5986 (1997).
28. Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128-134 (2002).
29. Heiser, P. W., Lau, J., Taketo, M. M., Herrera, P. L. & Hebrok, M. Stabilization of β-catenin impacts pancreas growth. Development 133, 2023-2032 (2006).
30. Bardeesy, N. et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad. Sci. USA 103, 5947-5952 (2006).
31. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
32. Izeradjene, K. et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11, 229-243 (2007).
33. Siveke, J. T. et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12, 266-279 (2007).
34. Morris, J. P. t., Cano, D. A., Sekine, S., Wang, S. C. & Hebrok, M. β-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120, 508-520 (2010).
35. Tanaka, T. et al. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Pancreas 42, 488-493 (2012).
36. Fukuda, A. et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19, 441-455 (2011).
37. Lesina, M. et al. Stat3/Socs3 activation by IL-6 transsignalling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456-469 (2011).
38. Corcoran, R. B. et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71, 5020-5029 (2011).
39. Aguirre, A. J. et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126 (2003).
40. Morton, J. P. et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139, 586-597 (2010).
41. Takehara, A. et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res. 67, 9704-9712 (2007).
42. Fusco, A. & Fedele, M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 7, 899-910 (2007).
43. Winslow, M. M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101-104 (2011).
44. Piscuoglio, S. et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology 60, 397-404 (2012).
45. Dozynkiewicz, M. A. et al. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev. Cell 22, 131-145 (2012).
46. Masui, T. et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res. 7, 3437-3443 (2001).
47. Wu, J. et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci. Trans. Med. 3, 92ra66 (2011).
48. Wu, J. et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc. Nat. Acad. Sci. USA 108, 21188-21193 (2011).
49. Furukawa, T. et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 1, 161 (2011).
50. Kanda, M. et al. Mutant GNAS detected in duodenal collections of secretinstimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62, 1024-1033 (2013).
51. Pan, F. C. et al. Spatiotemporal patterns of multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and injury-induced facultative restoration. Development 140, 751-764 (2013).
52. Solar, M. et al. Pancreatic exocrine duct cells give rise to insulin-producing β cells during embryogenesis but not after birth. Dev. Cell 17, 849-860 (2009).
53. Wang, X. et al. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumours. Int. J. Cancer 112, 636-642 (2004).
54. Kang, H., Cui, K. & Zhao, K. BRG1 controls the activity of the retinoblastoma protein via regulation of p21CIP1/WAF1/SDI. Mol. Cell Biol. 24, 1188-1199 (2004).
55. Guan, B., Wang, T. L. & Shih Ie, M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodelling, is a tumour suppressor in gynecologic cancers. Cancer Res. 71, 6718-6727 (2011).
56. Hendricks, K. B., Shanahan, F. & Lees, E. Role for BRG1 in cell cycle control and tumour suppression. Mol. Cell Biol. 24, 362-376 (2004).
57. Kia, S. K., Gorski, M. M., Giannakopoulos, S. & Verrijzer, C. P. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol. Cell Biol. 28, 3457-3464 (2008).
58. Bourgo, R. J. et al. SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol. Biol. Cell 20, 3192-3199 (2009).
59. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
60. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996-1006 (2002).
61. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).